Impact of fludarabine exposure and preinfusion disease burden on outcomes after tisagenlecleucel in responding patients. Patients were grouped based on fludarabine exposure (optimal vs suboptimal) and preinfusion disease burden (high vs low/no). (A) CIR among responders to tisagenlecleucel. (B) Cumulative incidence of composite end point among responders to tisagenlecleucel. (C) OS of all responding patients after tisagenlecleucel.